Sunday, June 5, 2016

LYNPARZA (olaparib): Latest Data Suggest Potential Overall Survival Advantage in Patients with Platinum Sensitive Ovarian Cancer

… III studies in breast
cancer, pancreatic cancer, and prostate cancer are also currently
underway … (PARP) inhibitor that may exploit tumor DDR
pathway deficiencies. Olaparib-induced cytotoxicity … Defects and Olaparib in
Metastatic Prostate Cancer. N Engl J Med 2015 …

No comments:

Post a Comment